Selective targeting of PARP-2 by genetic or pharmacological approaches blocks the interaction between PARP-2 and FOXA1, attenuating AR-mediated gene expression and inhibiting AR-positive prostate cancer growth [722]. Here, FOXA1 is linked to prostate carcinoma.